Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Waldenstrom Macroglobulinemia × Bortezomib × Clear all

Phase

Phase 2 18 Phase 1 6 Phase 1/2 4 Phase NA 1 Phase 4 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 7 Waldenstrom Macroglobulinemia 1 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Peripheral Nervous System Diseases 1 Neoplasms 1 Neoplasm, Residual 1 Immunoglobulin Light-chain Amyloidosis 1 Hematologic Neoplasms 1

Interventions

zanubrutinib 2 talquetamab 1 ibrutinib 1 Thiotepa 1 Thalidomide 1 Sirolimus 1 Rituximab 1 Radiotherapy 1 Prednisone 1 Filgrastim 1 Everolimus 1 Cyclophosphamide 1 Bortezomib 1 Antilymphocyte Serum 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02844322 2026-02-11

BDH-WM01

Institute of Hematology & Blood Diseases Hospital, China

Phase 4 Completed

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡